The companies have withdrawn a previous BLA after feedback from regulators at the FDA. The original application was based on ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Novo Nordisk AS (NVO) reports strong financial performance with a 24% sales increase, driven by demand for diabetes and ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Reports 9M 2024 net sales DKK 204.72B vs. DKK 166.4B last year. Lars Fruergaard Jorgensen, president and CEO, said: “We are pleased with ...

The Corner Booth The Quebec Liberals want semaglutide — also known as Ozempic — to be covered by medicare for weight loss.

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...